drugset / Trial / NCT05505448
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
The primary objective of the study is to evaluate the safety and tolerability of REGN14284 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). The secondary objectives of the study are: * To assess the concentration-time profile of REGN14284 in serum * To assess the immunogenicity of REGN14284
Timeline
- Start
- 2022-09-15
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGN14284 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.